Voyager Therapeutics, Inc. filings document regulatory disclosures for a Nasdaq-listed biotechnology company developing neurotherapeutics for central nervous system diseases. Its Form 8-K reports include quarterly and annual financial results, corporate updates, Regulation FD investor presentations, executive officer transitions and related exhibits covering pipeline and platform information.
Proxy materials describe annual meeting matters such as director elections, advisory executive compensation votes, auditor ratification, charter matters and proposals involving authorized capital. The filing record also identifies Voyager’s common stock, par value and Nasdaq Global Select Market listing, and formalizes governance and capitalization disclosures relevant to its public-company status.
Voyager Therapeutics, Inc. announced that Chief Medical Officer Toby Ferguson, M.D., Ph.D. has decided to resign from his role and all other positions with the company and its subsidiaries, effective February 20, 2026, to pursue a new opportunity.
The company states that Dr. Ferguson’s resignation is not due to any disagreement with Voyager. President and Chief Executive Officer Alfred W. Sandrock, Jr., M.D., Ph.D. has agreed to assume key responsibilities, including strategic guidance for clinical development programs, on an interim basis after the resignation becomes effective.
Swartz Robin reported open-market sale transactions in a Form 4 filing for VYGR. The filing lists transactions totaling 4,569 shares at a weighted average price of $3.85 per share. Following the reported transactions, holdings were 210,078 shares.
Sandrock Alfred reported open-market sale transactions in a Form 4 filing for VYGR. The filing lists transactions totaling 12,192 shares at a weighted average price of $3.78 per share. Following the reported transactions, holdings were 509,989 shares.
Carter Todd Alfred reported open-market sale transactions in a Form 4 filing for VYGR. The filing lists transactions totaling 3,525 shares at a weighted average price of $3.85 per share. Following the reported transactions, holdings were 153,193 shares.
Voyager Therapeutics Chief Medical Officer receives new equity awards. On February 6, 2026, Toby Ferguson was granted 45,000 restricted stock units (RSUs) and a stock option for 210,000 shares of common stock at an exercise price of $3.68 per share.
The RSUs vest over three years, in three equal annual installments starting one year after the grant date, subject to continued service. The stock option vests over four years, with 1/48th of the shares vesting monthly after the first month, also conditioned on continued service. Following the RSU grant, Ferguson directly beneficially owns 183,914 shares of common stock.
Voyager Therapeutics Chief Scientific Officer equity awards: Todd Alfred Carter received 33,000 restricted stock units and a stock option for 154,000 shares of Voyager Therapeutics common stock on February 6, 2026. The RSUs vest over three years and the option, with a $3.68 exercise price, vests monthly over four years, both based on continued service.
Voyager Therapeutics COO & CBO Robin Swartz reported new equity awards in the company. On February 6, 2026, Swartz was granted 45,000 shares of common stock for no cash consideration, issuable under restricted stock units awarded pursuant to the 2025 Stock Incentive Plan. Following this grant, Swartz beneficially owned 214,647 shares of common stock directly.
On the same date, Swartz received a stock option for 210,000 shares of common stock with an exercise price of $3.68 per share, expiring on February 6, 2036. The RSUs vest over three years in annual installments, and the option vests monthly over four years, in each case conditioned on continued service.
Voyager Therapeutics, Inc. President and CEO Alfred Sandrock reported equity awards on February 6, 2026. He received 402,500 stock options with a $3.68 exercise price, expiring on February 6, 2036, vesting monthly over four years, subject to continued service.
He was also awarded 86,250 restricted stock units, vesting in three equal annual installments starting one year after the grant date, also subject to continued service. Following these awards, he beneficially owned 522,181 shares of common stock, including 5,000 shares acquired under the company’s employee stock purchase plan.
Voyager Therapeutics’ Chief Financial Officer Nathan D. Jorgensen reported new equity awards. He received 32,250 shares of common stock for no cash cost, issuable under restricted stock units that vest over three years starting on February 6, 2026, subject to continued service.
He was also granted a stock option to buy 150,500 shares at an exercise price of $3.68 per share. This option vests monthly over four years starting on February 6, 2026. After these grants, he directly beneficially owned 156,084 shares of common stock.
A holder of VYGR common stock filed a notice of proposed sale under Rule 144 for 12,192 shares, to be sold through Fidelity Brokerage Services LLC on the NASDAQ, with an aggregate market value of $46,093.08. The issuer had 55,600,084 shares outstanding. The shares were acquired on 02/09/2026 through restricted stock vesting as compensation from the issuer.